EP0474517A2 — Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
Assigned to Wisconsin Alumni Research Foundation · Expires 1992-03-11 · 34y expired
What this patent protects
A novel use for 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1α,25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell l…
USPTO Abstract
A novel use for 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1α,25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell line.
Drugs covered by this patent
- Diprolene (BETAMETHASONE DIPROPIONATE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.